RegulatoryCompany release

Summit receives $2bn from AstraZeneca as FDA decision on ivonescimab nears

🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 04 Nov 2026

Summit Therapeutics says the FDA has set a 14 November 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC, with the regulator requiring statistically significant overall survival.

Summit Therapeutics reported third-quarter and nine-month 2026 results on 4 November, ending the quarter with $629.8 million in cash and investments. After quarter-end, the company received $2.0 billion from AstraZeneca in an equity investment.

The US Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) date of 14 November 2026 for Summit's biologics licence application (BLA). The application covers ivonescimab combined with chemotherapy in EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) after prior tyrosine kinase inhibitor (TKI) therapy. A PDUFA date is the target date by which the agency aims to complete its review.

The filing faces a notable hurdle. According to the company's summary, the FDA has said a statistically significant overall survival (OS) benefit is needed in this setting, and the HARMONi trial did not reach statistical significance on OS in its primary analysis.

Summit also reported new studies in bladder and kidney cancer. It noted that Phase III trials run by Akeso in China showed significant OS benefit. The summary does not say how those results relate to the US application.

What it means for your team

  • The 14 November PDUFA date is the next key regulatory event for ivonescimab, so teams tracking PD-(L)1/VEGF-class bispecifics should watch for the FDA's action.
  • The FDA's stated need for a statistically significant OS benefit in the post-TKI EGFR-mutated setting, set against HARMONi's primary OS result, is the central review question.
  • The new bladder and kidney cancer studies point to a broader development programme, which may matter for longer-term competitive and market-access planning.

Company's press release (SEC filing): Summit Therapeutics Inc. ↗

Article written by VigiEye from the official source (Summit Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →